ZOMETA® Patient Case Study On Renal Cell Carcinoma and Clinical Data

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Renal Cell Carcinoma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Renal Cell Carcinoma Patient Case Study - Carlo

Carlo V.

Aged 67 years
Retired accountant
Takes sculpting classes twice a week

Page

1 2 3

Carlo is not alone

20% to 25% of patients with advanced renal cell carcinoma will develop bone metastases¹
74% of patients with renal cell carcinoma and bone metastases will experience a skeletal-related event (SRE) without treatment²
SREs are generally defined as pathologic fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcemia³

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.